Seat No.:	Enrolment No.

## GUJARAT TECHNOLOGICAL UNIVERSITY M.PHARM - SEMESTER-2 EXAMINATION - SUMMER-2019

Subject Code: MRA202T Date: 29/05/2019

Subject Name: Regulatory Aspects of Herbal & Biologicals

Time: 10:30 AM TO 01:30 PM Total Marks: 80

## **Instructions:**

- 1. Attempt any five questions.
- 2. Make suitable assumptions wherever necessary.
- 3. Figures to the right indicate full marks.

Q.1	(a)	Write briefly about Market Authorization Application Data Requirements for Similar Biologics as per CDSCO.	06
	<b>(b)</b>	Write a note on Preclinical studies as per CDSCO.	05
	(c)	Write a note on Assessment of clinical safety and efficacy in the preparation of EU herbal monographs for well-established and traditional herbal medicinal products.	05
Q.2	(a) (b) (c)	Discuss Guidelines for IND application for Biosimilars as per USA.  Differentiate Biosimilars products and Biologics products.  Write a note on Pre-market approval process for Biologics in USA.	06 05 05
(l	(a)	Discuss about general requirements for 510(k) application for Biologics as per USA.	06
	(b) (c)	Write a note on Content and requirements of Plasma master file as per EU. Describe labelling and packing requirements for Blood products in EU.	05 05
Q.4	(a) (b) (c)	Describe various steps involved in obtaining an EU marketing authorisation. Discuss about control, monitoring and diagnosis of TSE as per EU. Discuss about pre-clinical development of Biologics as per EU.	06 05 05
	(a) (b)	Write briefly about guidelines on GDP for Biological products as per CDSCO. Discuss general format and content for post-authorisation safety studies as per EMA.	06 05
	(c)	Discuss Pharmacovigilance requirements for biological products as per CDSCO.	05
Q. 6	(a) (b) (c)	Discuss Schedule T for GMP requirements of herbal medicine in INDIA. Discuss the role and responsibilities of IHN. Discuss Good Agriculture and Collection Practices guideline as per AHPA.	06 05 05
Q.7	(a) (b) (c)	Enlist documents required for application of Herbal drug products in India.  Discuss standardization and quality evaluation of herbal products.  Discuss about preclinical data requirements for similar biologics.	06 05 05

\*\*\*\*\*\*